Effect of RevX solution adjunct to standard therapy in a patient with metastatic lung adenocarcinoma: A case report

Abstract

RevX solution is a liquid fermented grain extract obtained through a unique extraction technology, and its ingredients contain phytosterols, sulfonamides, organic acids, and anti-inflammatory substances. The adjunct treatment of RevX for lung adenocarcinoma has not yet been surveyed in vitro or in vivo experiments. A 71-year-old woman was diagnosed with lung adenocarcinoma. She underwent the targeted therapy and continually took the RevX solution (3 to 5 ml per day). Sixteen months after diagnosis and targeted therapy, multiple lung metastases appeared. After the second-line targeted therapy and wedge resection for 16 months, the patient was still alive. The distinct improvement of hypodynamia and fewer complication was found during targeted therapy treatment complemented with the RevX solution for longer than 4 years. Thus, the RevX solution might potentially be an adjuvant therapy for patients with metastatic lung adenocarcinoma.